Abstract:Parkinson’s disease (PD) is the most common movement disorder in the world, affecting 1–2 per 1,000 of the population. The main pathological changes of PD are damage of dopaminergic neurons in substantia nigra of the central nervous system and formation of Lewy bodies. These pathological changes also occur in the intestinal tract and are strongly associated with changes in intestinal flora. By reviewing the research progress in PD and its association with intestinal flora in recent years, this review expounded the mechanism of action between intestinal flora and PD as well as the transmission mode of α - synuclein in neurons. In clinical studies, β diversity of intestinal flora in PD patients was found to change significantly, with Lactobacillusaceae and Verrucomicrobiaceae being significantly increased and Lachnospiraceae and Prevotellaceae being significantly decreased. In addition, a longer PD course was associated with fewer bacteria and probiotics producing short chain fatty acids, but more pathogenic bacteria. Moreover, the motor symptoms of PD patients may be related to Enterobacteriaceae and bacteria. Most importantly, catechol-O-methyltransferase inhibitors and anticholinergic drugs could change the intestinal flora of PD patients and increase the harmful flora, whereas other anti-PD drugs such as levodopa, dopamine agonist, monoamine oxidase inhibitors, and amantadine did not have these effects. Probiotics, prebiotics, and synbiotics treatment had some potential values in improving the constipation of PD patients, promoting the growth of probiotics, and improving the level of intestinal inflammation. At present, there were only a few case studies and small sample studies which have found certain clinical efficacy of fecal microbiome transplants. Further studies are necessary to elaborate the relationship of PD with microbes.

Parkinson's Disease and the Microbiota-Gut-Brain Axis: Metabolites, Mechanisms, and Innovative Therapeutic Strategies Targeting the Gut Microbiota

Gut brain axis: an insight into microbiota role in Parkinson’s disease

Parkinson's disease and gut microbiota: from clinical to mechanistic and therapeutic studies

Oral, Nasal, and Gut Microbiota in Parkinson's Disease.

Gut Microbiota: A Novel Therapeutic Target for Parkinson's Disease

The interplay between gut microbiota and the brain-gut axis in Parkinson's disease treatment

Gut Microbiota-Induced Modulation of the Central Nervous System Function in Parkinson's Disease Through the Gut-Brain Axis and Short-Chain Fatty Acids

Research Progress of Microbiota-Gut-Brain Axis in Parkinson's Disease

Microbiota- Brain-Gut-Axis Relevance to Parkinson's Disease: Potential Therapeutic Effects of Probiotics

The role of the microbiota-gut-brain axis and intestinal microbiome dysregulation in Parkinson's disease

Gut microbiota and Parkinson's disease: potential links and the role of fecal microbiota transplantation

Association of Parkinson’s Disease With Microbes and Microbiological Therapy

Multidirectional associations between the gut microbiota and Parkinson's disease, updated information from the perspectives of humoral pathway, cellular immune pathway and neuronal pathway

The Role of the Gut Microbiota in the Pathogenesis of Parkinson's Disease

Gut Microbiota Approach—A New Strategy to Treat Parkinson’s Disease

The role of gut dysbiosis in Parkinson’s disease: mechanistic insights and therapeutic options

The microbiome–gut–brain axis in Parkinson disease — from basic research to the clinic

Interactions between gut microbiota and Parkinson's disease: The role of microbiota-derived amino acid metabolism

Emerging insights between gut microbiome dysbiosis and Parkinson’s disease: Pathogenic and clinical relevance

Gut Microbiota and Parkinson's Disease: Implications for Faecal Microbiota Transplantation Therapy

Gut Microbiota and Parkinson’s Disease: Implications for Faecal Microbiota Transplantation Therapy